{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:58:43Z","timestamp":1785761923417,"version":"3.56.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009252","name":"Science for Life Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.yexcr.2023.113527","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T15:50:52Z","timestamp":1678117852000},"page":"113527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Microscopy-based phenotypic monitoring of MDA-MB-231 spheroids allows the evaluation of phenotype-directed therapy"],"prefix":"10.1016","volume":"425","author":[{"given":"Loay","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Cougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bekiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Araceli Ruiz de Castroviejo Teba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"El Marrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Panneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2440-307X","authenticated-orcid":false,"given":"Louise","family":"Gsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hausser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.yexcr.2023.113527_bib1","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","article-title":"Molecular classification and molecular forecasting of breast cancer: ready for clinical application?","volume":"23","author":"Brenton","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113527_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca - Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.yexcr.2023.113527_bib3","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.yexcr.2023.113527_bib4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.yexcr.2023.113527_bib5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yexcr.2023.113527_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.yexcr.2023.113527_bib7","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.7150\/thno.31657","article-title":"Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy","volume":"9","author":"Flashner-Abramson","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.yexcr.2023.113527_bib8","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1200\/EDBK_158808","article-title":"Tumor heterogeneity and therapeutic resistance","volume":"36","author":"Lovly","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.yexcr.2023.113527_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/labinvest.2014.155","article-title":"Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology","volume":"95","author":"Heindl","year":"2015","journal-title":"Lab. Invest."},{"issue":"8","key":"10.1016\/j.yexcr.2023.113527_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/embor.2013.92","article-title":"Cancer heterogeneity--a multifaceted view","volume":"14","author":"De Sousa E Melo","year":"2013","journal-title":"EMBO Rep."},{"issue":"4260","key":"10.1016\/j.yexcr.2023.113527_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.trecan.2015.11.003","article-title":"Cancer evolution and the limits of predictability in precision cancer medicine","volume":"2","author":"Lipinski","year":"2016","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.yexcr.2023.113527_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bjc.6603024","article-title":"Epigenetics as a mechanism driving polygenic clinical drug resistance","volume":"94","author":"Glasspool","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.yexcr.2023.113527_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/BF02616120","article-title":"Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization","volume":"14","author":"Cailleau","year":"1978","journal-title":"In Vitro"},{"issue":"4","key":"10.1016\/j.yexcr.2023.113527_bib15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrclinonc.2010.194","article-title":"Preclinical development of molecular-targeted agents for cancer","volume":"8","author":"Ocana","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.yexcr.2023.113527_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000245","article-title":"Can animal models of disease reliably inform human studies?","volume":"7","author":"Worp van der","year":"2010","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.yexcr.2023.113527_bib17","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3892\/or.2015.3767","article-title":"Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer","volume":"33","author":"Imamura","year":"2015","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.yexcr.2023.113527_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semcancer.2005.06.009","article-title":"Gene expression perturbation in vitro\u2014a growing case for three-dimensional (3D) culture systems","volume":"15","author":"Birgersdotter","year":"2005","journal-title":"Semin. Cancer Biol."},{"issue":"16","key":"10.1016\/j.yexcr.2023.113527_bib19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10529-005-8652-8","article-title":"Role of E-cadherin molecules in spheroid formation of hepatocytes adhered on galactose-carrying polymer as an artificial asialoglycoprotein model","volume":"27","author":"Takei","year":"2005","journal-title":"Biotechnol. Lett."},{"issue":"3","key":"10.1016\/j.yexcr.2023.113527_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00441-005-0148-2","article-title":"Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and \u03b21-integrin","volume":"324","author":"Lin","year":"2006","journal-title":"Cell Tissue Res."},{"issue":"12","key":"10.1016\/j.yexcr.2023.113527_bib21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3727\/096368909X474258","article-title":"E-cadherin protects primary hepatocyte spheroids from cell death by a caspase-independent mechanism","volume":"18","author":"Luebke-Wheeler","year":"2009","journal-title":"Cell Transplant."},{"issue":"10","key":"10.1016\/j.yexcr.2023.113527_bib22","article-title":"Mammosphere Formation in breast carcinoma cell lines depends upon expression of E-cadherin","volume":"8","author":"Iglesias","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.yexcr.2023.113527_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers10080265","article-title":"Organotypic 3D models of the ovarian cancer tumor microenvironment","volume":"10","author":"Watters","year":"2018","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.yexcr.2023.113527_bib24","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s13277-015-4065-z","article-title":"Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo","volume":"37","author":"Szade","year":"2016","journal-title":"Tumor Biol."},{"issue":"31","key":"10.1016\/j.yexcr.2023.113527_bib25","doi-asserted-by":"crossref","first-page":"30472","DOI":"10.18632\/oncotarget.5401","article-title":"High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant","volume":"6","author":"Farnie","year":"2015","journal-title":"Oncotarget"},{"issue":"1A","key":"10.1016\/j.yexcr.2023.113527_bib26","first-page":"45","article-title":"Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features","volume":"27","author":"Takagi","year":"2007","journal-title":"Anticancer Res."},{"issue":"16","key":"10.1016\/j.yexcr.2023.113527_bib27","doi-asserted-by":"crossref","first-page":"25848","DOI":"10.18632\/oncotarget.15667","article-title":"Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies","volume":"8","author":"Arora","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.yexcr.2023.113527_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.f.359","article-title":"High-content analysis of biomarker intensity and distribution in 3D microtissues","volume":"9","author":"Waschow","year":"2012","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.yexcr.2023.113527_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6604851","article-title":"Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours","volume":"100","author":"Campone","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2023.113527_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.760055","article-title":"Trametinib inhibits the growth and aerobic glycolysis of glioma cells by targeting the PKM2\/c-myc Axis","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib31","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41467-019-13195-1","article-title":"Tumor diversity and the trade-off between universal cancer tasks","volume":"10","author":"Hausser","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib32","first-page":"113","article-title":"Growth of multicell spheroids in tissue culture as a model of nodular carcinomas","volume":"46","author":"Sutherland","year":"1971","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.yexcr.2023.113527_bib33","series-title":"SMARCA4 Regulates Spatially Restricted Metabolic Plasticity in 3D Multicellular Tissue [Internet]","author":"Cermakova","year":"2021"},{"issue":"6","key":"10.1016\/j.yexcr.2023.113527_bib34","first-page":"4708","article-title":"Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers","volume":"13","author":"Mota","year":"2017","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.yexcr.2023.113527_bib35","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ajpath.2013.05.033","article-title":"Triple-negative breast cancer and the need for new therapeutic targets","volume":"183","author":"Engebraaten","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"7718","key":"10.1016\/j.yexcr.2023.113527_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2023.113527_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2407-3-13","article-title":"Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications","volume":"3","author":"Nugoli","year":"2003","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.yexcr.2023.113527_bib38","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"key":"10.1016\/j.yexcr.2023.113527_bib39","series-title":"R: A Language and Environment for Statistical Computing","year":"2020"},{"key":"10.1016\/j.yexcr.2023.113527_bib40","series-title":"RStudio: Integrated Development Environment for R","year":"2019"},{"issue":"8","key":"10.1016\/j.yexcr.2023.113527_bib41","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/2472555220924478","article-title":"Identification of a triple drug combination that is synergistically cytotoxic for triple-negative breast cancer cells using a novel combination discovery approach","volume":"25","author":"Ahmad","year":"2020","journal-title":"SLAS Discov Adv Sci Drug Discov"},{"issue":"19","key":"10.1016\/j.yexcr.2023.113527_bib42","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1039\/D0AN00979B","article-title":"Oxygen consumption rate of tumour spheroids during necrotic-like core formation","volume":"145","author":"Mukomoto","year":"2020","journal-title":"Analyst"},{"key":"10.1016\/j.yexcr.2023.113527_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmolb.2020.00020","article-title":"Routine optical clearing of 3D-cell cultures: simplicity forward","volume":"7","author":"N\u00fcrnberg","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"10.1016\/j.yexcr.2023.113527_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ejca.2014.11.018","article-title":"PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel","volume":"51","author":"Coupe","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"16","key":"10.1016\/j.yexcr.2023.113527_bib45","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast cancer cell line classification and its relevance with breast tumor subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.yexcr.2023.113527_bib47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cels.2022.07.006","article-title":"Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer","volume":"13","author":"Groves","year":"2022","journal-title":"Cell Syst"},{"issue":"3","key":"10.1016\/j.yexcr.2023.113527_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nmeth.3254","article-title":"Inferring biological tasks using Pareto analysis of high-dimensional data","volume":"12","author":"Hart","year":"2015","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69026-7","article-title":"Unveiling functional heterogeneity in breast cancer multicellular tumor spheroids through single-cell RNA-seq","volume":"10","author":"Muci\u00f1o-Olmos","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","article-title":"A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds","volume":"167","author":"Bruna","year":"2016","journal-title":"Cell"},{"issue":"34","key":"10.1016\/j.yexcr.2023.113527_bib51","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.yexcr.2023.113527_bib52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","article-title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","volume":"16","author":"Hurvitz","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.yexcr.2023.113527_bib53","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bjc.2013.467","article-title":"A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer","volume":"109","author":"Sun","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2023.113527_bib54","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/annonc\/mdu482","article-title":"A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors","volume":"26","author":"Tolcher","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482723000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482723000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:45:28Z","timestamp":1757997928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482723000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0014482723000745"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2023.113527","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microscopy-based phenotypic monitoring of MDA-MB-231 spheroids allows the evaluation of phenotype-directed therapy","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2023.113527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113527"}}